What Are Fentanyl Test Strips?

Fentanyl test strips were not originally designed for drug checking. They were developed by a diagnostics company in Canada as clinical urine drug screening devices intended to detect fentanyl and its primary metabolite, norfentanyl, in patient urine samples. The original manufacturer produces strips under a clinical brand in an ISO 13485-certified facility. The shift came when harm reduction advocates recognized that these same immunoassay strips could be used to test illicit drug samples before consumption, effectively repurposing a clinical tool into a life-saving intervention.

Access to fentanyl test strips has expanded dramatically in recent years, driven by federal funding and innovative distribution models. At least 33 states and the District of Columbia now operate harm reduction vending machines, many of which dispense fentanyl test strips alongside naloxone and other supplies free of charge and without requiring identification. Oklahoma, for example, operates 27 naloxone vending machines, each stocked with 54 fentanyl test strip packages. States like New York allow certified harm reduction providers to order up to 1,200 test strips at a time, while Pennsylvania provides strips at no cost through its Department of Drug and Alcohol Programs.

A watershed moment for fentanyl test strips came in April 2021, when the Substance Abuse and Mental Health Services Administration (SAMHSA) and the CDC jointly announced that federal grant funding could be used to purchase fentanyl test strips for harm reduction purposes. This policy change applied to major programs including CDC\\

One of the most compelling features of fentanyl test strips is their extremely low cost. Standard single-antibody strips retail for approximately one dollar per strip when purchased in bulk, though pricing can vary by distributor and volume. By comparison, more advanced drug checking technologies like mass spectrometry or Fourier-transform infrared spectroscopy can cost tens of thousands of dollars per instrument. For large-scale public health distribution, the economics are even more favorable when strips are purchased at government or wholesale pricing.

While fentanyl test strips are a valuable harm reduction tool, they have well-documented limitations that users and program administrators must understand. Standard single-epitope test strips target one specific molecular region of fentanyl, which means they can miss structurally modified analogs that do not share that epitope. A 2023 study published in Harm Reduction Journal tested two major brands of fentanyl test strips against 251 synthetic opioids and found significant "blind spots": of the 251 compounds screened, 50 were not detectable by either brand, and 80 were detectable by one brand but not the other. Carfentanil, an ultra-potent fentanyl analog responsible for deadly overdose outbreaks, has particularly low detection sensitivity on standard strips.

The illicit drug supply is constantly evolving, presenting challenges that outpace the capabilities of standard fentanyl test strips. Xylazine, a veterinary tranquilizer not approved for human use, was designated as an "emerging drug threat" by the White House Office of National Drug Control Policy in April 2023 after it was found increasingly mixed with fentanyl. In some Northeast markets, xylazine has been detected in 20-35% of illicit fentanyl samples. Standard fentanyl test strips cannot detect xylazine, prompting the development and distribution of separate xylazine-specific test strips.

The documented limitations of conventional fentanyl test strips have spurred innovation in drug checking technology. Standard strips rely on a single antibody targeting one molecular epitope on the fentanyl molecule, which inherently limits their ability to detect the hundreds of structurally diverse fentanyl analogs now circulating in the drug supply. The 2023 Harm Reduction Journal study that screened 251 synthetic opioids explicitly recommended that "rapid immunoassays and other drug checking instruments that can detect a wider range of fentanyl analogs including carfentanil need to be prioritized." Broad-spectrum approaches, which use antibodies targeting multiple distinct regions of the fentanyl molecular structure, represent a significant advancement. By covering more structural variations, broad-spectrum strips can detect a substantially broader range of analogs, including many that fall into the "blind spots" of conventional single-epitope strips. This technological evolution is critical as illicit chemists continue to modify fentanyl\\

Using a fentanyl test strip is straightforward and requires no technical expertise. First, set aside a small amount of the drug to be tested, at least 10 milligrams, in a clean, dry container such as a small cup or bottle cap. Add approximately half a teaspoon (about 2.5 milliliters) of water and mix or stir until the substance is dissolved. Place the wavy or absorbent end of the test strip into the liquid and allow it to absorb for about 15 seconds.